Mongomery discusses SRX valuation, page-8

I hadn't considered that to be honest. My line of thinking was that although it's a larger trial, the data will still be very much fragmented and be a collection of "mini trials" if you will. Similar to the data we already have. In no way am I assuming it will be positive based on this alone, but I'm hoping it won't be far off.

Sorry if I came off as blunt mark, was short on time!